PatientID: HDR122

Okitobba 06, 2023

## Color Code

HR: High-Level Resistance
PLR: Potential Low-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance
S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|---|---|---|---|
| **PI** | ATV | **S** | |
| | DRV | **S** | |
| | FPV | **S** | |
| | IDV | **S** | |
| | LPV | **S** | |
| | NFV | **S** | |
| | SQV | **S** | |
| | TPV | **S** | |
| **NRTI** | ABC | **S** | K219R |
| | AZT | **PLR** | |
| | D4T | **PLR** | |
| | DDI | **S** | |
| | FTC | **S** | |
| | LMV | **S** | |
| | TDF | **S** | |
| **NNRTI** | DOR | **IR** | V106M;V179D |
| | EFV | **HR** | |
| | ETR | **PLR** | |
| | NVP | **HR** | |
| | RPV | **PLR** | |

# Appendix

## Drug abbreviations in full

| DRUG.CLASS | ABBREVIATION | DRUG.NAME |
|---|---|---|
| **PI** | ATV | Atazanavir |
| | DRV | Darunavir |
| | FPV | Fosamprenavir |
| | IDV | Indinavir |
| | LPV | Lopinavir |
| | NFV | Nelfinavir |
| | SQV | Saquinavir |
| | TPV | Tipranavir |
| **NRTI** | ABC | Abacavir |
| | AZT | Azidothymidine |
| | DFT | Stavudine |
| | DDI | Didanosine |
| | FTC | Emtricitabine |
| | LMV | Lamivudine |
| | TDF | Tenofovir |
| **NNRTI** | DOR | Doravirine |
| | EFV | Efavirenz |
| | ETR | Etravirine |
| | NVP | Nevirapine |
| | RPV | Rilpivirine |
| **INSTI** | BIC | Bictegravir |
| | CAB | Cabotegravir |
| | DTG | Dolutegravir |
| | EVG | Elvitegravir |
| | RAL | Raltegravir |

## Comments

| DRUG.CLASS | COMMENTS |
|---|---|
| **PI** | |
| **NRTI** | K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs. |
| **NNRTI** | V106M is a non-polymorphic mutation that confers high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it reduces DOR susceptibility about 3-fold. |
| | V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility. |
| **INSTI** | |